Pharmafile Logo

Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

September 24, 2025 |  

Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across Inizio Evoke, Inizio Engage, and Inizio Medical.

PM360AwardsInizio

We’re proud to announce that our teams across Inizio EvokeInizio Engage, and Inizio Medical have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation in healthcare marketing. 

The PM360 Trailblazer Awards honor the most impactful initiatives, strategies, and companies driving change in the healthcare industry across eight core categories. This year, our recognition spans multiple disciplines – highlighting our expertise in artificial intelligence (AI), data analytics, patient and healthcare professional (HCP) education, and persistence/adherence programs, as well as our standing as a top industry partner. 

Our 2025 PM360 trailblazer award finalist categories 

Driving innovation across healthcare marketing 

These finalist recognitions demonstrate how our connected capabilities empower life sciences organizations to achieve greater patient engagement, educational impact, and data-driven decision-making. Our work leverages cutting-edge AI and analytics, compelling creative strategies, and deep scientific expertise to deliver measurable results for our clients and ultimately improve healthcare outcomes. 

Looking ahead 

We are honored to be recognized alongside such inspiring organizations and partners. These six finalist nominations reflect the passion, creativity, and expertise of our teams across Inizio. 

Good luck to all of this year’s finalists – we look forward to celebrating the incredible work shaping the future of healthcare marketing. Stay tuned for the results and follow our updates on LinkedIn. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Pegasus’s Approach to Measurement Wins 3 Gold’s at 2014 AMEC International Summit in Amsterdam

Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam

Pegasus Crowned Health Consultancy of the Year at 2014 Sabre Emea Awards

Brighton consultancy adds top honour to its award wins

Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards

Brighton-based independent healthcare specialist looks to add award to growing list of accolades

Pegasus Moves to Brighton

Top UK Healthcare Communications Consultancy Moves to Brighton

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding